Zacks: Analysts Expect Theravance Biopharma Inc (NASDAQ:TBPH) Will Post Quarterly Sales of $14.96 Million

Share on StockTwits

Wall Street analysts forecast that Theravance Biopharma Inc (NASDAQ:TBPH) will announce sales of $14.96 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Theravance Biopharma’s earnings. The lowest sales estimate is $11.00 million and the highest is $20.40 million. Theravance Biopharma posted sales of $12.84 million in the same quarter last year, which suggests a positive year-over-year growth rate of 16.5%. The business is scheduled to issue its next earnings report on Tuesday, November 5th.

On average, analysts expect that Theravance Biopharma will report full year sales of $58.99 million for the current fiscal year, with estimates ranging from $45.78 million to $76.20 million. For the next year, analysts anticipate that the business will report sales of $97.99 million, with estimates ranging from $74.18 million to $129.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.22) by $0.50. The business had revenue of $26.15 million for the quarter, compared to analyst estimates of $13.92 million.

Several analysts have recently commented on TBPH shares. BidaskClub downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Friday. Cantor Fitzgerald set a $55.00 target price on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Theravance Biopharma in a report on Monday, September 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $44.25.

Shares of TBPH stock traded up $0.18 on Friday, hitting $17.97. The stock had a trading volume of 6,981 shares, compared to its average volume of 203,083. The business has a 50 day moving average of $21.01 and a 200 day moving average of $20.21. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -4.50 and a beta of 1.64. Theravance Biopharma has a 12-month low of $15.18 and a 12-month high of $31.26.

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Theravance Biopharma by 1.4% during the second quarter. Vanguard Group Inc. now owns 3,932,787 shares of the biopharmaceutical company’s stock valued at $64,223,000 after buying an additional 54,562 shares during the period. BlackRock Inc. grew its position in Theravance Biopharma by 3.1% during the second quarter. BlackRock Inc. now owns 3,832,682 shares of the biopharmaceutical company’s stock valued at $62,587,000 after buying an additional 116,009 shares during the period. Northern Trust Corp grew its position in Theravance Biopharma by 0.6% during the second quarter. Northern Trust Corp now owns 553,629 shares of the biopharmaceutical company’s stock valued at $9,041,000 after buying an additional 3,547 shares during the period. Jacobs Levy Equity Management Inc. grew its position in Theravance Biopharma by 15.3% during the second quarter. Jacobs Levy Equity Management Inc. now owns 309,873 shares of the biopharmaceutical company’s stock valued at $5,060,000 after buying an additional 41,060 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Theravance Biopharma by 5.5% during the second quarter. Charles Schwab Investment Management Inc. now owns 251,994 shares of the biopharmaceutical company’s stock valued at $4,116,000 after buying an additional 13,042 shares during the period. Institutional investors own 84.16% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Recommended Story: Mutual Funds

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.